Has the rate of progression to AIDS changed in recent years?

AIDS

Volumn 11, Issue 13, 1997, Pages 1611-1618

  Carré, Nicolas ^a   Prins, Maria ^b   Meyer, Laurence ^a   Brettle, Raymond P ^c   Robertson, J Roy ^d   McArdle, Helen ^e   Goldberg, David J ^f   Zangerle, Robert ^g   Coutinho, Roel A ^b   Van Den Hoek, Anneke ^b  

^a BICÊTRE HOSPITAL   (France)

^b MUNICIPAL HEALTH SERVICE   (Netherlands)

^c CITY HOSPITAL   (United Kingdom)

^d Edinburgh Drug Addiction Study   (United Kingdom)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f RUCHILL HOSPITAL   (United Kingdom)

^g UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

AIDS onset; Calendar period; Injecting drug users; Sexual exposure group; Treatments; Year of seroconversion

Indexed keywords

CD4 ANTIGEN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; DISEASE COURSE; EUROPE; FRANCE; HOMOSEXUALITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SEROCONVERSION; STATISTICS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HIV SEROPOSITIVITY; HUMANS; MALE; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 9844247552     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199713000-00010     Document Type: Article

References (36)

1. Alcabez P, Munoz A, Vlahov D, Friedland G: Incubation period of human immunodeficiency disease. Epidemiol Rev 1993, 15:303-318.
2. Veugelers PJ, Page KA, Tindall B, et al.: Determinants of HIV disease progression among homosexual men registered in the Tricontinental Seroconverter Study. Am J Epidemiol 1994, 140:747-758.
3. Centers for Disease Control: Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men - New York City and California. MMWR 1981, 30:305-308.
4. Keet IPM, Veugelers PJ, Koot M, et al.: Temporal trends of the natural history of HIV-1 infection following seroconversion between 1984 and 1993 [letter]. AIDS 1996, 10:1601-1602.
5. O'Brien TR, Hoover DR, Rosemherg PS, et al.: Evaluation of secular trends in CD4+ lymphocyte loss among human immunodeficiency virus type 1 (HlV-1)-ifected men with known dates of seroconversion. Am J Epidemiol 1995, 142:636-642.
6. Holmberg S, Conley LJ, Luby SP, Cohn S, Wong LC, Vlahov D: Recent infection with human immunodeficiency virus and possible loss of CD4 lymphocytes. J Acquir Immune Defic Syndr 1995, 9:291-296.
7. de Ronde A, Schuurman R, Goudsmit J, van den Hoek A, Boucher C: First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, the Netherlands [letter]. AIDS 1996, 10:231-232.
8. Ewald PW: Evolution of infectious disease. New York: Oxford University Press; 1994.
9. Hessol NA, Koblin B, van Griensven GJP, et al.: Progression of human immunodeficiency virus type 1 (HIV-1) infection among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York city, and San Fransisco, 1978-1991. Am J Epidemiol 1994, 139:1077-1087.
10. Centers for Disease Control: Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987, 36:3S-15S.
11. Craven DE, Liebman HA, Hagerty C, et al.: AIDS in intravenous drug users: issues related to enrolment in clinical trials. J Acquir Immune Defic Syndr 1990, 3 (suppl 2):S45 S50.
12. Rosenberg PS, Gail MH, Schrager LK, et al.: National AIDS incidence trends and the extent of zidovudine therapy in selected demographic and transmission groups. J Acquir Immune Defic Syndr 1991, 4:392-401.
13. Solomon L, Franck R, Vlahov D, Astemborski J: Utilization of health services in a cohort of intravenous drug users with known HIV-1 serostatus. Am J Public Health 1991, 81:1285-1290.
14. Easterbrook PJ, Keruly JC, Creagh-Kirk T, et al.: Racial and ethnic differences in outcome in zidovudine-teated patients with advanced HIV disease. JAMA 1991, 266:2713-2718.
15. Prins M, Veugelers PJ for the European Seroconverter Study and the Tricontinental Seroconverter Study: Comparison of progression and non-progression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion. AIDS 1997, 11:621-631.
16. Boufassa F, Bachmeyer C, Carré N, et al.: Influence of neurological manifestations of primary infection on disease progression. J Infect Dis 1995, 171:1190-1195.
17. Carré N, Meyer L, Boufassa F et al.: High risk of HIV disease progression after infection through a sexual partner with AIDS. AIDS 1996, 10:77-80.
18. Gallant JE, Moore RD, Chaisson RE: Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 1994, 120:932-944.
19. Holmberg SD, Buchbinder SP, Conley LJ, et al.: The spectrum of medical conditions and symptoms before acquired immunodeficiency syndrome in homosexual and bisexual men infected with the human immunodeficiency virus. Am J Epidemiol 1993, 141:395-404.
20. Steel CM, Ludlam CA, Beatson D, et al.: HLA haplotype AI B8 DR3 as a risk factor for HIV-related disease. J ancet 1990, i:1185-1188.
21. Darby SC, Ewart DW, Giangrande PLF, Spooner RJD, Rizza CR, for the UK Haemophilia Centre Directors' Organisation: Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. Lancet 1996, 347:1573-1579.
22. Tersmette M, Schuitemaker H: Virulent HIV strains? AIDS 1993, 7:1123-1125.
23. Weiss PJ, Brodine SK, Goforth RR, et al.: Initial low CD4 lymphocyte counts in recent human immunodeficiency virus infection and lack of association with identified coinfections. J Infect Dis 1992, 166:1149-1153.
24. Gorham ED, Garland FC, Mayers DL, et al.: CD4 lymphocyte counts within 24 months of human immunodeficiency virus seroconversion. Arch Intern Med 1993, 153:869-876.
25. Galai N, Cozzi Lepri A, Vlahov D, et al.: Temporal trends of initial CD4 cell counts following human immunodeficiency virus seroconversion in Italy, 1985-1992. Am J Epidemiol 1996, 143:278-282.
26. Sinicco A, Fora R, Raiteri R, et al.: Is the clinical course of HIV-1 changing? Cohort study. BMJ 1997, 314:1232-1237.
27. Schwartländer B, Horsburgh Jr CR, Hamouda O, Skarabis H, Koch MA: Changes in the spectrum of AIDS-defining conditions and decrease in CD4+ lymphocyte counts at AIDS manifestation in Germany from 1986 to 1991 AIDS 1992, 6:413-420.
28. Graham NMH, Zeger SL, Parl LP, et al.: Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. Lancet 1991, 338:265-269
29. Broers B, Morabia A, Hirschel B: A cohort study of drug users' compliance with zidovudine treatment. Arch Intern Med 1994, 154:1121-1127.
30. Dorruci MD, Pezzotti P, Phillips AN, Alliegro MB, Rezza G, the HIV Italian Seroconversion Study: Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. AIDS 1997, 11:461-467.
31. Fisch MA, Richman DD, Hansen N, et al.: The safely and efficacy of zidovudine (AZT) in the treatment of patients with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double blind placebo-controlled trial. Ann Intern Med 1990, 112:727-737.
32. Volderbing PA, Lagakos SW, Koch MA, et al.: Zidovudine in asymptomatic human immune deficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990, 322:941-949.
33. Hamilton JD, Hartigan P, Simberkoff M, et al.: A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. N Engl J Med 1992, 326:437-443.
34. Longini IM, Clark WS, Karon JM: Effect of routine use of therapy in slowing the clinical course of human immunodeficiency virus (HIV) infection in a population-based cohort. Am J Epidemiol 1993, 137:1229-1240.
35. Mulder JW, Cooper DA, Mathiesen L, et al.: Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. AIDS 1994, 8:313-321.
36. 3: demonstration of efficacy in a prospective multicenter trial. Clin Infect Dis 1996, 23:1282-1286.